Pacira BioSciences, Inc. (PCRX)
NASDAQ: PCRX · Real-Time Price · USD
22.40
-0.14 (-0.62%)
At close: Aug 6, 2025, 4:00 PM
22.25
-0.15 (-0.67%)
After-hours: Aug 6, 2025, 5:20 PM EDT

Altus Power Statistics

Total Valuation

PCRX has a market cap or net worth of $1.04 billion. The enterprise value is $1.25 billion.

Market Cap1.04B
Enterprise Value 1.25B

Important Dates

The last earnings date was Tuesday, August 5, 2025, after market close.

Earnings Date Aug 5, 2025
Ex-Dividend Date n/a

Share Statistics

PCRX has 46.30 million shares outstanding. The number of shares has decreased by -15.61% in one year.

Current Share Class 46.30M
Shares Outstanding 46.30M
Shares Change (YoY) -15.61%
Shares Change (QoQ) -2.29%
Owned by Insiders (%) 0.96%
Owned by Institutions (%) 112.33%
Float 45.83M

Valuation Ratios

PE Ratio n/a
Forward PE 7.12
PS Ratio 1.47
Forward PS 1.38
PB Ratio 1.34
P/TBV Ratio 3.38
P/FCF Ratio 9.09
P/OCF Ratio 7.91
PEG Ratio n/a
Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 8.22, with an EV/FCF ratio of 10.67.

EV / Earnings n/a
EV / Sales 1.77
EV / EBITDA 8.22
EV / EBIT 20.16
EV / FCF 10.67

Financial Position

The company has a current ratio of 2.38, with a Debt / Equity ratio of 0.83.

Current Ratio 2.38
Quick Ratio 1.79
Debt / Equity 0.83
Debt / EBITDA 3.61
Debt / FCF 5.39
Interest Coverage 3.32

Financial Efficiency

Return on equity (ROE) is -15.57% and return on invested capital (ROIC) is 2.66%.

Return on Equity (ROE) -15.57%
Return on Assets (ROA) 2.43%
Return on Invested Capital (ROIC) 2.66%
Return on Capital Employed (ROCE) 5.06%
Revenue Per Employee $893,478
Profits Per Employee -$161,342
Employee Count790
Asset Turnover 0.44
Inventory Turnover 1.84

Taxes

In the past 12 months, PCRX has paid $20.91 million in taxes.

Income Tax 20.91M
Effective Tax Rate n/a

Stock Price Statistics

The stock price has increased by +12.29% in the last 52 weeks. The beta is 0.48, so PCRX's price volatility has been lower than the market average.

Beta (5Y) 0.48
52-Week Price Change +12.29%
50-Day Moving Average 23.73
200-Day Moving Average 22.59
Relative Strength Index (RSI) 49.56
Average Volume (20 Days) 640,076

Short Selling Information

The latest short interest is 5.46 million, so 11.79% of the outstanding shares have been sold short.

Short Interest 5.46M
Short Previous Month 5.60M
Short % of Shares Out 11.79%
Short % of Float 11.92%
Short Ratio (days to cover) 10.63

Income Statement

In the last 12 months, PCRX had revenue of $705.85 million and -$127.46 million in losses. Loss per share was -$2.81.

Revenue705.85M
Gross Profit 474.08M
Operating Income 61.97M
Pretax Income 100.55M
Net Income -127.46M
EBITDA 151.96M
EBIT 61.97M
Loss Per Share -$2.81
Full Income Statement

Balance Sheet

The company has $445.86 million in cash and $631.40 million in debt, giving a net cash position of -$185.54 million or -$4.01 per share.

Cash & Cash Equivalents 445.86M
Total Debt 631.40M
Net Cash -185.54M
Net Cash Per Share -$4.01
Equity (Book Value) 757.77M
Book Value Per Share 16.88
Working Capital 432.45M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was $134.52 million and capital expenditures -$17.46 million, giving a free cash flow of $117.07 million.

Operating Cash Flow 134.52M
Capital Expenditures -17.46M
Free Cash Flow 117.07M
FCF Per Share $2.53
Full Cash Flow Statement

Margins

Gross margin is 67.16%, with operating and profit margins of 8.78% and -18.06%.

Gross Margin 67.16%
Operating Margin 8.78%
Pretax Margin -15.10%
Profit Margin -18.06%
EBITDA Margin 21.53%
EBIT Margin 8.78%
FCF Margin 16.59%

Dividends & Yields

PCRX does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Years of Dividend Growth n/a
Payout Ratio n/a
Buyback Yield 15.61%
Shareholder Yield 15.61%
Earnings Yield -11.98%
FCF Yield 11.00%
Dividend Details

Analyst Forecast

The average price target for PCRX is $27.14, which is 21.16% higher than the current price. The consensus rating is "Buy".

Price Target $27.14
Price Target Difference 21.16%
Analyst Consensus Buy
Analyst Count 7
Revenue Growth Forecast (5Y) 7.39%
EPS Growth Forecast (5Y) n/a
Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value n/a
Lynch Upside n/a
Graham Number n/a
Graham Upside n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date n/a
Split Type n/a
Split Ratio n/a

Scores

Altman Z-Score n/a
Piotroski F-Score 6